全球前列腺癌診斷及治療市場:各種類、診斷法、治療方法、地區 - 成長,趨勢,預測(2018年∼2023年)

Prostate Cancer Diagnostics and Therapy Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 124 Pages | 商品交期: 2-3個工作天內



  • 全貌
  • 簡介
  • 目錄




第1章 簡介

  • 市場定義

第2章 調查方法

第3章 摘要整理

第4章 主要影響要素

第5章 市場概要

  • 目前市場方案
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第6章 成長要素,阻礙因素,市場機會,課題

  • 市場成長要素
    • 前列腺癌的罹患率高
    • 治療藥的創新與基因學及蛋白質體學領域的發展
    • 醫藥品開發領域的公共部門及民間部門的資金籌措的增加
    • 癌症、腫瘤診斷及治療藥的技術發展
  • 市場阻礙因素
    • 診斷檢驗相關的成本高
    • 臨床試驗的成功率低
    • 治療的副作用
  • 市場機會
  • 主要課題

第7章 市場區隔

  • 各類型
    • 良性前列腺肥大症
    • 前列腺腺癌
    • 小細胞癌症
    • 其他
  • 各診斷法
    • 細胞切片檢查
    • 數位直腸檢驗
    • 臨床檢驗
    • 診斷成像
  • 各治療法
    • 化療
    • 近接治療
    • 放射線治療
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第8章 競爭情形

  • 合併、收購分析
  • 協定,合作,夥伴關係
  • 新產品的銷售

第9章 主要業者

  • Abbott
  • AstraZeneca
  • Astellas Pharma Inc.
  • Bayer AG
  • BioMark Diagnostics Inc.
  • Sanofi
  • Ipsen
  • TOLMAR Pharmaceuticals, Inc.
  • Indevus Pharmaceuticals Inc.
  • Dendreon Inc.
  • 其他企業

第10章 市場未來展望

Product Code: 47468

The prostate cancer diagnostics and therapy market was expected to grow with a CAGR of nearly 6.1% during the forecast period, 2021-2026.

Cancer diagnosis and treatment care are hard hit by the sudden emergence of the COVID-19 infection due to the halt in diagnostic procedures and surgical procedures. Moreover, as per many studies, cancer patients especially prostate cancer patients are more susceptible to coronavirus than individuals without cancer, as they are in an immunosuppressive state caused by the malignancy and anticancer treatment. So, they are majorly suggested to stay at home and avoid all non-emergent diagnoses and treatment. According to the Union for International Cancer Control's (UICC), there is a significant decrease in cancer diagnostics rates in the United States during the pandemic. This is expected to impact the market growth however, this negative growth is anticipated to persist for a short duration.

The major factor attributing to the growth of the market studied is an aging population and a high prevalence rate of prostate cancer. Prostate cancer is the second most common type of cancer in the male population. About 80% of men who reach 80 years of age are diagnosed with it. As per the data published by Globocan 2020, the prevalence of prostate cancer was found to be 1,414,259 or 7.3% of the total cancer cases worldwide. As prostate cancer is more common in the elderly population the rising aging is the population in the world is also expected to propel market growth. For instance, as per World Population Ageing Report 2019, there were 703 million people aged 65 years or over in the world in 2019, and this number of older persons is projected to double and reach 1.5 billion in 2050. In addition, several government bodies are also taking initiatives in order to expand the treatment and diagnostic options. For instance, in 2018, the Australian government and Movember Foundation announced a partnership to combat prostate cancer by investing AUD 12 million in the ground-breaking new research teams focused on conducting life-saving prostate cancer researches and decreasing the number of deaths caused by the disease. Hence, owing to all the aforementioned the market is anticipated to propel at high growth rates. However, the high cost of prostate cancer drugs and the low success rate of clinical trials is expected to hinder the market growth.

Key Market Trends

The Transrectal Ultrasound (TRUS) Segment is Expected to Grow at Rapid Pace

The transrectal ultrasound (TRUS) guided biopsy is also among the common diagnostic procedure performed for prostate cancer, which is still considered as the viable option. It is quick and convenient to the provider, along with a familiar approach to most of the urologists and a low risk of urinary retention. It is very useful to observe the abnormal areas of the prostate, size, and shape of the prostate. TRUS is considered a viable option in some cases as an important alternative for the early detection of prostate cancer. For patients who cannot undergo MRI procedures, due to claustrophobia, metal implants, or lack of insurance coverage, TRUS is a good option with clinical benefits.

Philips is one of the major companies, which is advancing in both transrectal and transperineal biopsy. BK Medical is among the others, which has established itself well in PSA testing and TRUS as the primary diagnostic pathway, for more than 25 years.

In recent years, the American Urology Association and the European Association of Urology have recommended the TRUS biopsy, which is the most common and useful alternative transperineal approach. In several cases, the patients are often suffering from associated diseases, where the TURS biopsy has a considerable edge over other procedures, thus, it is widely known and accepted. At present, with several new approaches coming up with imaging, the growth of this segment estimated to be steady, during the forecast period.

North America is Expected to Retain the Largest Market Share During the Period of Forecast

Geographically, North America is anticipated to dominate the market share owing to the factors such as increasing prevalence of prostate cancer coupled with rising awareness and increasing research and development in this region. According to the American Cancer Society, in 2018, an estimate of 164,690 new prostate cancer cases was identified and 29,430 deaths were reported in the United States.

The USFDA is taking steps to enhance the growth of the cancer therapy market by approving drugs, which are in the clinical phase, thus accelerating the clinical developments. Companies and research organizations are investing in R&D, hence, the market is expanding at a fast pace.

The rising number of prostate cancer cases is creating huge opportunities for market players. The major market players are focusing on R&D activities, to bring new and reliable treatments to the market. For instance, in March 2019, MiR Scientific launched tests for prostate and bladder cancer, and in 2018, Clovis Oncology received Breakthrough Therapy Designation from USFDA for Rubraca(rucaparib) for the treatment of BRCA1/2-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Market players in Canada are focusing on various growth strategies, such as new product launches, partnerships, mergers, and acquisitions, etc. For instance, in Feb 2018, Janseen Pharmaceutical received Health Canada approval for a new indication for ZYTIGA (abiraterone acetate) thereby, broadening its use for the treatment of newly diagnosed metastatic prostate cancer. In addition to promising pipeline drugs, such as Apalutamide, the market in this region is expected to propel.

Competitive Landscape

Several large drug and equipment manufacturers exist within the global prostate cancer diagnostic and therapy market, and their status as a major player lies primarily within specific product markets. Key players in the market include Abbott Laboratories, Astellas Inc., AstraZeneca, Bayer HealthCare AG, Cellanyx Diagnostics Inc, Dendreon Corporation, Ferring Pharmaceuticals, Ipsen Group, Sanofi-Aventis, Tolmar Inc, GE Healthcare, Siemens Healthineers, and F. Hoffmann-La Roche AG, among others. Market players are constantly focusing on market expansion through innovative product launches. For instance, in Feb 2019, Blue Earth Diagnostics announced the first commercial production of Axumin(fluciclovine ) in Italy, with the first Italian patients being dosed. Axuminis a novel molecular imaging agent approved in the European Union for use in PET imaging to detect prostate cancer in men, those who are experiencing suspected recurrence

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support



  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Aging Population and High Prevalence Rate of Prostate Cancer
    • 4.2.2 Innovation in Drugs and Developments in Genomics and Proteomics
    • 4.2.3 Increasing Government Initiatives for Cancer Awareness
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Prostate Cancer Drugs
    • 4.3.2 Low Success Rate of Clinical Trials
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Type
    • 5.1.1 Benign Prostatic Hyperplasia
    • 5.1.2 Prostatic Adenocarcinoma
    • 5.1.3 Small Cell Carcinoma
    • 5.1.4 Other Types
  • 5.2 By Modality
    • 5.2.1 Diagnosis
      • Tissue Biopsy
      • Transrectal Ultrasound
      • Clinical Laboratory Examination
      • Prostate-specific Antigen Testing
      • Urine Testing
      • Diagnostic Imaging
    • 5.2.2 Treatment
      • Surgery
      • Radiation Therapy
      • Therapeutics
      • Hormone Therapy
      • Chemotherapy
      • Other Treatments
  • 5.3 Geography
    • 5.3.1 North America
      • United States
      • Canada
      • Mexico
    • 5.3.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.3.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East & Africa
    • 5.3.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 Abbvie Inc.
    • 6.1.2 Astellas Pharma Inc.
    • 6.1.3 AstraZeneca PLC
    • 6.1.4 Bayer AG
    • 6.1.5 Becton, Dickinson and Company
    • 6.1.6 Dendreon Pharmaceuticals LLC
    • 6.1.7 F. Hoffmann-La Roche Ltd.
    • 6.1.8 Hologic Inc.
    • 6.1.9 Ipsen SA
    • 6.1.10 Johnson & Johnson Services, Inc
    • 6.1.11 Koninklijke Philips NV
    • 6.1.12 Merck & Co. Inc.
    • 6.1.13 Pfizer Inc.
    • 6.1.14 Sanofi-Aventis
    • 6.1.15 Thermo Fisher Scientific